
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1606620/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine, 2010, 363, 221-232.	27.0	2,275
2	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine, 2013, 369, 417-427.	27.0	611
3	ANCA-Associated Vasculitis: Core Curriculum 2020. American Journal of Kidney Diseases, 2020, 75, 124-137.	1.9	249
4	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. Journal of the American Society of Nephrology: JASN, 2015, 26, 976-985.	6.1	137
5	Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent. Transplantation, 2002, 73, 1933-1936.	1.0	125
6	Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: a case report and review of literature. Clinical Transplantation, 2000, 14, 586-591.	1.6	103
7	Incidence and Outcomes of BK Virus Allograft Nephropathy among ABO- and HLA-Incompatible Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1320-1327.	4.5	98
8	Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following <scp>Twoâ€Dose SARS</scp> – <scp>CoV</scp> â€2 Messenger <scp>RNA</scp> Vaccination. Arthritis and Rheumatology, 2022, 74, 28-32.	5.6	91
9	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Experience. Transplantation, 2011, 91, 1370-1375.	1.0	71
10	Contraceptive Options for Women With a History of Solid-Organ Transplantation. Transplantation, 2013, 95, 1183-1186.	1.0	60
11	Ureteral Stents: A Novel Risk Factor for Polyomavirus Nephropathy. Transplantation, 2007, 84, 433-436.	1.0	54
12	Results of Repeat Renal Transplantation After Graft Loss From BK Virus Nephropathy. Transplantation, 2011, 92, 781-786.	1.0	47
13	Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis. Journal of Community Hospital Internal Medicine Perspectives, 2018, 8, 339-344.	0.8	47
14	Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Seminars in Arthritis and Rheumatism, 2015, 45, 67-69.	3.4	43
15	Antineutrophil Cytoplasmic Antibody Vasculitis Associated with Influenza Vaccination. American Journal of Nephrology, 2013, 38, 174-178.	3.1	42
16	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Kidney International Reports, 2018, 3, 1039-1049.	0.8	41
17	Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome. BMC Nephrology, 2013, 14, 210.	1.8	39
18	Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. Clinical Rheumatology, 2013, 32, 1317-1322.	2.2	39

#	Article	IF	CITATIONS
19	Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab. American Journal of Nephrology, 2015, 41, 296-301.	3.1	39
20	Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis. CKJ: Clinical Kidney Journal, 2017, 10, 470-474.	2.9	36
21	Renal Transplantation in the ANCA-Associated Vasculitides. American Journal of Transplantation, 2007, 7, 2657-2662.	4.7	34
22	Rituximab for treatment of severe renal disease in ANCA associated vasculitis. Journal of Nephrology, 2016, 29, 195-201.	2.0	33
23	Persistent or New Onset Microscopic Hematuria in Patients with Small Vessel Vasculitis in Remission: Findings on Renal Biopsy. Journal of Rheumatology, 2012, 39, 1413-1417.	2.0	27
24	Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: AÂReview. American Journal of Kidney Diseases, 2022, 79, 582-600.	1.9	26
25	Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant. Transplant International, 2013, 26, 1225-1231.	1.6	25
26	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1888-1893.	5.6	25
27	The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum. Autoimmunity Reviews, 2021, 20, 102986.	5.8	25
28	A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. Clinical Rheumatology, 2016, 35, 953-960.	2.2	23
29	The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. Journal of Nephrology, 2021, 34, 185-190.	2.0	23
30	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. Nephrology Dialysis Transplantation, 2022, 37, 1400-1410.	0.7	21
31	Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. Journal of Nephrology, 2015, 28, 17-27.	2.0	20
32	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrology Dialysis Transplantation, 2019, 34, 301-308.	0.7	20
33	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology, 2021, 60, 4654-4661.	1.9	20
34	Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response―by Bonelli <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e164-e164.	0.9	17
35	Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis. Seminars in Arthritis and Rheumatism, 2014, 44, 198-201.	3.4	16
36	Relevance of ANCA positivity at the time of renal transplantation in ANCA associated vasculitis. Journal of Nephrology, 2017, 30, 147-153.	2.0	16

#	Article	IF	CITATIONS
37	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. American Journal of Nephrology, 2017, 46, 231-238.	3.1	15
38	Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists. Kidney International Reports, 2021, 6, 1197-1199.	0.8	15
39	Outcomes of hydralazine induced renal vasculitis. European Journal of Rheumatology, 2018, 5, 5-8.	0.6	15
40	ANCA Status or Clinical Phenotype — What Counts More?. Current Rheumatology Reports, 2021, 23, 37.	4.7	14
41	Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2014, 30 Suppl 1, i159-63.	0.7	13
42	Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study. BMC Nephrology, 2015, 16, 88.	1.8	13
43	Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis. American Journal of Nephrology, 2018, 48, 465-471.	3.1	13
44	Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis. Kidney International, 2022, 101, 414-415.	5.2	13
45	Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti–neutrophil cytoplasmic antibody vasculitis. Kidney International, 2021, 100, 1124-1127.	5.2	11
46	Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2022, 37, 2190-2200.	0.7	11
47	Dapsone induced hemolysis in a patient with ANCA associated glomerulonephritis and normal G6PD level and implications for clinical practice: case report and review of the literature. SpringerPlus, 2015, 4, 29.	1.2	10
48	Characteristics and Outcomes of COVID-19 in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Kidney International Reports, 2021, 6, 806-809.	0.8	10
49	Renal Transplant in Wegener's Granulomatosis Compared to Microscopic Polyangiitis. Journal of Rheumatology, 2010, 37, 1705-1708.	2.0	9
50	Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. Seminars in Arthritis and Rheumatism, 2014, 43, 778-783.	3.4	9
51	PEXIVAS challenges current ANCA-associated vasculitis therapy. Nature Reviews Nephrology, 2020, 16, 373-374.	9.6	9
52	Renal Transplantation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Perspectives. Kidney and Blood Pressure Research, 2020, 45, 157-165.	2.0	9
53	Clinical Characteristics of Hydralazine-induced Lupus. Cureus, 2019, 11, e4996.	0.5	9
54	Fibrillary Glomerulonephritis Presenting as Rapidly Progressive Glomerulonephritis. American Journal of Kidney Diseases, 2012, 60, 157-159.	1.9	8

#	Article	IF	CITATIONS
55	Clinical excellence in nephrology: Examples from the published literature. BMC Nephrology, 2015, 16, 141.	1.8	8
56	Crystal-storing histiocytosis. Kidney International, 2016, 89, 507.	5.2	8
57	Renal transplantation in anti-neutrophil cytoplasmic antibody vasculitis. Expert Review of Clinical Immunology, 2018, 14, 235-240.	3.0	8
58	Antiâ€glomerular basement membrane disease (Goodpasture disease): From pathogenesis to plasma exchange to IdeS. Therapeutic Apheresis and Dialysis, 2021, , .	0.9	8
59	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. Kidney International Reports, 2021, 6, 2903-2907.	0.8	8
60	Immunotherapy for ANCA-associated vasculitis during the COVID-19 pandemic. European Journal of Rheumatology, 2020, 7, S121-S128.	0.6	8
61	Outcome of Renal Transplantation in Patients With Both ANCA and Anti-GBM Antibodies. Transplantation, 2012, 94, e30-e31.	1.0	7
62	Advances in Therapy for ANCA-Associated Vasculitis. Current Rheumatology Reports, 2012, 14, 509-515.	4.7	7
63	Treatment Outcomes of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Patients Over Age 75 Years: A Meta-Analysis. American Journal of Nephrology, 2020, 51, 327-336.	3.1	7
64	ANCA-associated vasculitis in scleroderma: AÂrenal perspective. Clinical Nephrology, 2018, 90, 413-418.	0.7	7
65	Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. ImmunoTargets and Therapy, 2015, 4, 173.	5.8	6
66	Uncommon presentations in ANCA vasculitis: clinical characteristics and outcomes. Clinical Rheumatology, 2019, 38, 2195-2199.	2.2	6
67	Venous Thrombotic Events in ANCA-Associated Vasculitis: Incidence and Risk Factors. Kidney360, 2020, 1, 258-262.	2.1	6
68	Application of the ANCA Renal Risk Score in the United States: A Single-Center Experience. Kidney Medicine, 2021, 3, 686-688.	2.0	6
69	Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course. , 2022, 9, 93-99.		6
70	Renal involvement in primary SjĶgren's syndrome: natural history and treatment outcome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 123-132.	0.8	6
71	Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022. American Journal of Kidney Diseases, 2022, 80, 393-405.	1.9	6
72	Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology. Kidney International Reports, 2018, 3, 671-676.	0.8	5

#	Article	IF	CITATIONS
73	Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis. American Journal of Nephrology, 2019, 50, 386-391.	3.1	5
74	Long-term Clinical Course of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Patients off Maintenance Therapy. Cureus, 2018, 10, e2372.	0.5	5
75	SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis. Kidney International Reports, 2022, 7, 629-632.	0.8	5
76	Keeping Up with the Times. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1078-1080.	4.5	3
77	Polyomavirus-Associated Nephropathy. Medicine (United States), 2011, 90, 296-302.	1.0	2
78	Falling through the cracks of vasculitis classificationa report of three patients. CKJ: Clinical Kidney Journal, 2011, 4, 327-330.	2.9	2
79	Serum and urinary metabolites discriminate disease activity in ANCA associated glomerulonephritis in a pilot study. Journal of Nephrology, 2021, , 1.	2.0	2
80	Ranolazine-induced Elevation of Creatinine Kinase in the Absence of Statin Usage. Cureus, 2018, 10, e2832.	0.5	2
81	Bamlanivimab Decreases Severe Outcomes of SARS-CoV-2 Infection in Patients With Antineutrophil Cytoplasmic Antibody Vasculitis. Kidney International Reports, 2022, 7, 651-652.	0.8	2
82	Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis. Cureus, 2019, 11, e6367.	0.5	1
83	Characterization of interstitial infiltrates in MPO and PR3 anti-neutrophil cytoplasmic antibody glomerulonephritis. Journal of Nephrology, 2021, , 1.	2.0	Ο
84	An unusual complication of peritoneal dialysis. Cleveland Clinic Journal of Medicine, 2018, 85, 352-354.	1.3	0
85	Additional Refinement of CKD Prognostication Using Lymphatic Vessel Density: IgA Nephropathy as the Role Model?. Kidney International Reports, 2022, 7, 667-670.	0.8	Ο
86	The devil is in the details: Approach to refractory hypokalemia. Cleveland Clinic Journal of Medicine, 2022, 89, 182-188.	1.3	0